title: Development of Nephrotic Syndrome in a Patient with Rheumatoid Arthritis Treated with Certolizumab.
authors: Division of Rheumatology, Department of Medicine, Mayo Clinic; Butendieck.Ronald@mayo.edu.
authors: Ronald R
authors: RR
authors: Butendieck
authors: Preliminary Internal Medicine Resident, Department of Medicine, Mayo Clinic;
authors: Tanya
authors: T
authors: Bhattacharya
authors: Assistant Professor of Laboratory Medicine and Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.
authors: Xochiquetzal
authors: X
authors: Geiger
mesh_terms: D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000188:drug therapy*; D001707:Biopsy, Needle; D000068582:Certolizumab Pegol / Q000009:adverse effects* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000139:chemically induced* / Q000473:pathology*; D020127:Recovery of Function; D012720:Severity of Illness Index; D028761:Withholding Treatment
chemical_list: D000068582:Certolizumab Pegol